Tarsons swings to ₹0.34 Cr consolidated loss in Q2 FY27 despite 21% YoY revenue growth
PAT -110.4% YoY · revenue +20.8% · margins compressing
₹123.65 Cr
+20.8% YoY
₹-0.34 Cr
-110.4% YoY
-0.27%
-3.3pp YoY
₹-0.06
Tarsons' consolidated revenue grew 20.8% YoY (and 12.2% QoQ) to ₹123.65 Cr in Q2 FY27, in line with the ~21% pace the company itself flagged in its results announcement, but the Group swung to a net loss of ₹0.34 Cr against a profit of ₹3.32 Cr a year ago — a second straight quarterly loss after Q1 FY27's ₹1.44 Cr, though the loss did narrow sequentially. No analyst consensus for this specific quarter turned up in a search of brokerage previews, so the print is best read against management's own prior commentary rather than a street number (vsStreet unknown). On that score it was better than feared: operating margin (OPM) came in at 25.14%, ahead of the ~23.6% full-year level management guided to on the Q1 call (assuming input costs persisted), and up from Q1 FY27's 23.57% — even as it stayed below the year-ago 26.82%, which is the YoY compression that actually defines the quarter.
Q2 FY-2027 vs prior quarters
The loss originates below the operating line, not in it: group segment EBITDA (before D&A) rose 6.7% YoY to ₹35.24 Cr, but depreciation jumped 25.7% YoY to ₹28.26 Cr and finance costs rose 27.5% YoY to ₹6.60 Cr as the Panchla/Amta capex is absorbed into the P&L — together ₹34.86 Cr against that ₹35.24 Cr of EBITDA. H1 FY27 depreciation of ₹55.28 Cr is tracking toward the top end of management's guided ₹105-110 Cr full-year range. Notably, the loss sits entirely outside the standalone (India) entity: standalone PAT was ₹3.09 Cr (EPS ₹0.58) on 24.5% YoY standalone revenue growth, while the consolidated loss (EPS -₹0.06) is a subsidiary/consolidation-level effect per the auditors' notes on the German units (Nerbe plus/Nerbe R&D) — a divergence readers should note before reading the headline loss as an India-business problem. No exceptional items were booked this quarter, so the loss reflects ongoing operations, not a one-off; no management press release was available to cross-check company framing against these numbers.
The stock went into the print at ₹312.55, down 7.5% over the past month of trading.
For context: revenue is at a 6-quarter high.
FY'27 EBITDA margin similar to Q1 (23.6%) if input costs persist; depreciation to peak at ₹105-110 Cr full-year; Panchla/Amta to contribute 20-25% of FY'28 standalone revenue; new product portfolio target ₹65-70 Cr in FY'28; capex substantially complete, focus now on utilization.
— This quarter: met
W1
Full-year depreciation vs management's ₹105-110 Cr guidance — H1 FY27 already at ₹55.28 Cr, tracking toward the top of that range.
W2
Whether OPM continues its sequential recovery (23.57% → 25.14%) or compresses again on input costs, against management's ~23.6% full-year reference point.
W3
Panchla/Amta utilization ramp — management guided 20-25% of FY28 standalone revenue from these facilities; watch for capacity-utilization updates.
Figures in source were ₹ Million (unaudited, reviewed); no exceptional items this quarter at the quarterly level (the ₹11.27mn new-labour-code charge sat only in H1/FY26 full-year columns); standalone is profitable (PAT ₹3.09 Cr) while consolidated shows a loss (-₹0.34 Cr) — divergence traced in auditor notes 6-7 to subsidiary/consolidation items tied to the German units.